GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Synmosa Biopharma Corp (ROCO:4114) » Definitions » Research & Development

Synmosa Biopharma (ROCO:4114) Research & Development : NT$260 Mil (TTM As of Dec. 2024)


View and export this data going back to 2003. Start your Free Trial

What is Synmosa Biopharma Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. Synmosa Biopharma's Research & Development for the three months ended in Dec. 2024 was NT$71 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2024 was NT$260 Mil.

Synmosa Biopharma Research & Development Historical Data

The historical data trend for Synmosa Biopharma's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Synmosa Biopharma Research & Development Chart

Synmosa Biopharma Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 159.53 214.37 215.28 210.91 259.72

Synmosa Biopharma Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 57.84 64.53 57.42 66.29 71.49

Synmosa Biopharma Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$260 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Synmosa Biopharma  (ROCO:4114) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Synmosa Biopharma Research & Development Related Terms

Thank you for viewing the detailed overview of Synmosa Biopharma's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.

Synmosa Biopharma Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Synmosa Biopharma Corp (ROCO:4114) » Definitions » Research & Development
Comparable Companies
TPE:1789 ROCO:4105 TPE:3705 TPE:1707 ROCO:6576 ROCO:6620 TPE:1720 TPE:4119 ROCO:6785 ROCO:1799 ZTS XTER:MRK NSE:SUNPHARMA TSE:4502 LSE:HLN XSWX:GALD XSWX:SDZ HKSE:03692 NSE:DIVISLAB XTAE:TEVA
Traded in Other Exchanges
N/A
Address
No. 6, Gongye 1st Road, Hukou Township, Hsinchu County, Hsinchu, TWN
Website
https://www.synmosa.com.tw
Synmosa Biopharma Corp is engaged in the research and development, manufacturing, marketing, and distribution of pharmaceutical products, medical devices, cosmetics, animal drugs, chemical food additives, and beverages. It is also involved in manufacturing and sales, and environmental drugs wholesale (retail), as well as the import and export of related businesses. The company provides prescription, OTC medicines, and healthcare products under its Synmosa trademark. The reporting segments of the company are; the Generic Drugs segment which derives key revenue, and the Active Pharmaceutical Ingredients segment.

Synmosa Biopharma Headlines

No Headlines